You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,096,876


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,096,876
Title:Engineered microbes and methods for microbial oil overproduction from cellulosic materials
Abstract: The invention relates to engineering microbial cells for utilization of cellulosic materials as a carbon source, including xylose.
Inventor(s): Stephanopoulos; Gregory (Winchester, MA), Tai; Mitchell (Seattle, WA)
Assignee: Massachusetts Institute of Technology (Cambridge, MA)
Application Number:13/923,607
Patent Claims:1. An isolated oleaginous cell comprising a nucleic acid construct that increases expression of: a xylose reductase (XYL1) gene product and a xylitol dehydrogenase (XYL2) gene product; wherein the nucleic acid construct comprises an intron and (a) an expression cassette comprising a nucleic acid sequence encoding the XYL1 and XYL2 gene products under the control of a suitable homologous or heterologous promoter, and/or (b) a nucleic acid sequence that modulates the level of expression of the XYL1 and XYL2 gene products when inserted into the genome of the cell.

2. The isolated oleaginous cell of claim 1, further comprising a genetic modification that increases expression of a xylulokinase (XYL3) gene product.

3. The isolated oleaginous cell of claim 1, further comprising a genetic modification that increases expression of a diacylglycerol acyltransferase (DGA) gene product, an acetyl-coA carboxylase (ACC) gene product, a stearoyl-CoA-desaturase (SCD) gene product, and/or an ATP-citrate lyase (ACL) gene product.

4. The isolated oleaginous cell of claim 1, wherein the intron is downstream of a transcription initiation site of the nucleic acid sequence encoding one or more of the gene products.

5. The isolated oleaginous cell of claim 4, wherein the intron is within the nucleic acid sequence encoding one or more of the XYL1 and XYL2 gene products.

6. The isolated oleaginous cell of claim 1, wherein the nucleic acid construct inhibits or disrupts the natural regulation of a native gene encoding the XYL1 and XYL2 gene products resulting in overexpression of the native gene.

7. The isolated oleaginous cell of claim 1, wherein the increased expression of the XYL1 and XYL2 gene products confers a beneficial phenotype for the conversion of a carbon source to a fatty acid, fatty acid derivative and/or triacylglycerol (TAG) to the cell.

8. The isolated oleaginous cell of claim 7, wherein the beneficial phenotype is a modified fatty acid profile, a modified TAG profile, an increased fatty acid and/or triacylglycerol synthesis rate, an increase conversion yield, an increased triacylglycerol accumulation in the cell, and/or an increased triacylglycerol accumulation in a lipid body of the cell.

9. The isolated oleaginous cell of claim 8, wherein the synthesis rate, yield or accumulation of a fatty acid or a TAG of the cell is at least 2-fold increased as compared to unmodified cells of the same cell type.

10. The isolated oleaginous cell of claim 7, wherein the cell converts a carbon source to a fatty acid or a TAG at a conversion rate within the range of about 0.025 g/g to about 0.32g/g (g TAG produced/g Glucose consumed).

11. The isolated oleaginous cell of claim 1, wherein the cell is an oleaginous yeast cell.

12. The isolated oleaginous cell of claim 1, wherein the cell is a Yarrowia lipolytica cell, a Hansenula polymorpha cell, a Pichia pastoris cell, a Saccharomyces cerevisiae cell, a S. bayanus cell, a S. K. lactis cell, a Waltomyces lipofer cell, a Mortierella alpine cell, a Mortierella isabellina cell, a Hansenula polymorpha cell, a Mucor rouxii cell, a Trichosporon cutaneu cell, a Rhodotorula glutinis cell, a Saccharomyces diastasicus cell, a Schwanniomyces occidentalis cell, a S. cerevisiae cell, a Pichia stipitis cell, or a Schizosaccharomyces pombe cell.

13. A culture, comprising the oleaginous cell of claim 1.

14. The culture of claim 13, further comprising a carbon source.

15. The culture of claim 14, wherein the carbon source comprises a fermentable sugar.

16. A method, comprising contacting a carbon source with an isolated oleaginous cell of claim 1, and incubating the carbon source contacted with the cell under conditions suitable for at least partial conversion of the carbon source into a fatty acid or a triacylglycerol by the cell.

17. The method of claim 16, wherein the carbon source is a fermentable sugar.

18. The method of claim 17, wherein the fermentable sugar is a C5 and/or a C6 sugar.

19. A method for increasing production of fatty acid or triacylglycerol by an oleaginous cell, comprising culturing the oleaginous cell of claim 1 with at least two types of carbon sources, wherein the first type of carbon source contains or is xylose, and wherein the second type of carbon source is a carbon source other than xylose, whereby the production of fatty acid or triacylglycerol by the oleaginous cell is improved relative to culturing the cell or the culture without the second type of carbon source.

20. The method of claim 19, wherein the second type of carbon source contains or is a C2 carbon source, a C3 carbon source, a CS carbon source other than xylose or a C6 carbon source.

Details for Patent 9,096,876

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2032-06-22
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2032-06-22
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2032-06-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.